Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials

Medical experts compare the updated results of a Phase II trial and KEYNOTE B-61, both presented at ASCO 2024, giving a comprehensive overview of these pivotal studies.

CN24_BTL_RCC_Seg10_Trials

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Overview of RCC Histology and Incidence Rates

EP: 2.CLEAR Trial Updates From ASCO 2024

EP: 3.TKIs, Disease Progression and Subsequent Therapy in RCC

EP: 4.ASCO 2024 Updates: nccRCC + Chromophobe RCC

EP: 5.PAPMET Phase II Trial Advances Cancer Treatment Landscape

EP: 6.Chromophobe Renal Cell Carcinoma: Key Features and Diagnosis

EP: 7.Examining Predictors of Chromophobe Renal Cell Carcinoma Recurrence

EP: 8.ASCO 2024: Abstract 4512 Overview

EP: 9.Key Takeaways in Renal Cell Carcinoma from Abstract 4512

Now Viewing

EP: 10.Phase II and KEYNOTE B-61: Comparative Analysis of Cancer Trials

Recent Videos

Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making

Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions

MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer

Second-Line Treatment for Gastric Adenocarcinoma

Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

Gastric Adenocarcinoma: Current Treatment Landscape

Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

Esophageal/Gastric Adenocarcinoma Standard of Care

BESPOKE: Study Design, Efficacy End Points and Methods